(NASDAQ: GH) Guardant Health's forecast annual revenue growth rate of 24.81% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.86%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.18%.
Guardant Health's revenue in 2026 is $1,080,215,000.On average, 28 Wall Street analysts forecast GH's revenue for 2026 to be $173,573,307,061, with the lowest GH revenue forecast at $163,893,512,244, and the highest GH revenue forecast at $180,998,903,085. On average, 28 Wall Street analysts forecast GH's revenue for 2027 to be $222,767,880,720, with the lowest GH revenue forecast at $201,419,292,151, and the highest GH revenue forecast at $255,122,263,396.
In 2028, GH is forecast to generate $280,183,649,977 in revenue, with the lowest revenue forecast at $243,320,869,715 and the highest revenue forecast at $314,527,031,588.